Bath & Body Works, Inc.
—- Market cap
- —
- Debt
- +$3.89B
- Cash
- −$953.00M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BBWI stock price vs HAE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HAE's multiple
Needs HAE P/E.
Implied fair value · at BBWI's multiple
Needs BBWI P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BATH & BODY WORKS, INC. · implied price per share
Bear
$26.50
Base
$31.55
Bull
$40.51
HAEMONETICS CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Victoria's Secret & Co.
BBWI vs VSCO
ABERCROMBIE & FITCH CO /DE/
BBWI vs ANF
ESTEE LAUDER COMPANIES INC
BBWI vs EL
Ulta Beauty, Inc.
BBWI vs ULTA
Sally Beauty Holdings, Inc.
BBWI vs SBH
BECTON DICKINSON & CO
BBWI vs BDX
BAXTER INTERNATIONAL INC
BBWI vs BAX
LivaNova PLC
BBWI vs LIVN
STERIS plc
BBWI vs STE
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BBWI can sustain its current profitability and avoid further growth deterioration, then BBWI looks attractive versus HAE because it trades at far lower valuation multiples despite stronger ROIC and better margins.
BBWI trades at a deep discount to HAE on valuation: 7.1x P/E versus 36.6x, 0.6x P/S versus 2.6x, and 5.4x EV/EBITDA versus 16.6x. The current price of $21.97 sits near the low end of its historical band and far below HAE-implied price of $113.89, suggesting the market is valuing BBWI far more conservatively than HAE.
Supporting Metrics